| Developers: | Neuronetics |
| Date of the premiere of the system: | July 2022 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Announcement of a device for the treatment of anxiety depression
In July 2022, Neuronetics released the NeuroStar machine, which developers say allows for the treatment of anxiety symptoms in adult patients suffering from major depressive disorder, also known as anxiety depression.
NeuroStar is a non-drug, non-invasive treatment that can improve the quality of life of people suffering from neurological diseases when traditional medicines do not help. According to epidemiological data as of July 2022, depression belongs to the group of the most common disorders found in both psychiatric and general practice. In a study undertaken by the World Health Organization in 1999, it was found that depression and anxiety occur and coexist most often in general medical practice, which largely overlap each other both in clinical symptoms and developmental mechanisms.
 | Many people suffering from major depressive disorder also experience symptoms of anxiety, and these patients with anxiety depression are more likely to have severe depression and are more likely to think about suicide. This new indication means that doctors can now tell patients about the benefits of NeuroStar to improve anxiety symptoms! We would like to recognize the contribution of healthcare institutions across the country that have collaborated with us to help create the world's largest database of depression research findings, "said Neuronetics President and CEO Keith Sullivan. |  |
Neuronetics said in a press release that the U.S. Department of Health approved the use of real-world data analyzed using the patented TrakStar platform. This database contains digital data of patients treated with NeuroStar in more than 1,000 centers, which provides a large sample from a diverse group of patients treated in clinical practice. Results from the TrakStar study from 664 patients with anxiety depression showed that 65.5% achieved a clinically meaningful response, exceeding the prespecified overall study success criterion of at least 50% response.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |